A review on targeting tumor microenvironment: The main paradigm shift in the mAb-based immunotherapy of solid tumors
Monoclonal antibodies (mAbs) as biological macromolecules have been remarked the large
and growing pipline of the pharmaceutical market and also the most promising tool in …
and growing pipline of the pharmaceutical market and also the most promising tool in …
[HTML][HTML] Three distinct mechanisms underlying human γδ T cell-mediated cytotoxicity against malignant pleural mesothelioma
Y Umeyama, H Taniguchi, H Gyotoku, H Senju… - Frontiers in …, 2023 - frontiersin.org
Introduction Malignant pleural mesothelioma (MPM) is a rare and highly aggressive thoracic
tumor with poor prognosis and limited therapeutic options. Although immune checkpoint …
tumor with poor prognosis and limited therapeutic options. Although immune checkpoint …
True Benefits of Immune Checkpoint Inhibitors in the Treatment of Malignant Pleural Mesothelioma in Japan
K Kuribayashi, J Hirano - 2024 - preprints.org
Abstract In February 2004, the Food and Drug Administration (FDA) was the first to approve
the combination of cisplatin (CDDP) and pemetrexed (PEM) as standard first-line …
the combination of cisplatin (CDDP) and pemetrexed (PEM) as standard first-line …